Concepedia

Cheyenne Pagan

CP

Statistics

Publications

3

Citations

172

H-Index

3

Active since

2021

Affiliations

Dana-Farber Cancer Institute(Current)

University of Pennsylvania

Johns Hopkins Medicine

AstraZeneca (United Kingdom)

Johns Hopkins University

Cheyenne Pagan is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and cancer pharmacology.

ORCID

Publications per year

2021–2023

3

Publications

3

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Payal D. Shah, Stephanie L. Wethington, Cheyenne Pagan et al. · Gynecologic Oncology · 2021 · 117 citations · Full text

, , +17

Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

Stephanie L. Wethington, Payal D. Shah, Lainie P. Martin et al. · Journal of Clinical Oncology · 2021 · 31 citations

, , +16

SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Sujana Movva, Sahar Matloob, Elizabeth A. Handorf et al. · Clinical Cancer Research · 2023 · 24 citations

, , +17

1–3 of 3